|Day Low/High||3.45 / 3.62|
|52 Wk Low/High||3.44 / 9.40|
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ACIW, AMC, CTRP, GSIT, ITGR, JNP, KFFB, MD, MDSO, NJR, VECO Downgrades: NEM, TFX, TTEC Initiations: CNAT, OTEL Read on to get TheStreet Quant Ratings' detailed report:
Investors eyeing a purchase of Conatus Pharmaceuticals Inc stock, but cautious about paying the going market price of $4.07/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the April 2018 put at the $2.50 strike, which has a bid at the time of this writing of 10 cents.
The most recent short interest data has been released for the 10/31/2017 settlement date, which shows a 642,982 share decrease in total short interest for Conatus Pharmaceuticals Inc , to 1,461,190, a decrease of 30.56% since 10/13/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Pan-caspase Inhibitor IDN-7314 Reduces Liver Injury Due to Intestinal Bacteria Imbalance Resulting from Restricted Bile Flow in Mouse Model of PSC
Emricasan Improves and Sustains Key Functions in Cirrhotic Liver Cells
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.